Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 495.65% | -6.79% | 27.63% | -47.47% | 7.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 495.65% | -6.79% | 27.63% | -47.47% | 7.84% |
| Cost of Revenue | 668.57% | 11.33% | 1,499.31% | 427.77% | 40.00% |
| Gross Profit | 486.34% | -8.69% | -49.40% | -88.76% | 6.52% |
| SG&A Expenses | 96.81% | 4.82% | 178.58% | 90.62% | 37.42% |
| Depreciation & Amortization | 5.69% | 109.33% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.75% | -2.20% | 69.78% | 91.85% | 49.38% |
| Operating Income | 73.83% | -1.71% | -77.73% | -280.60% | -59.66% |
| Income Before Tax | 88.52% | -2.39% | -226.05% | -650.09% | -25.32% |
| Income Tax Expenses | 1,788.57% | -- | -- | 194.59% | 32.04% |
| Earnings from Continuing Operations | 81.36% | -79.67% | -220.49% | -674.39% | -25.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.36% | -79.67% | -220.49% | -674.39% | -25.76% |
| EBIT | 73.83% | -1.71% | -77.73% | -280.60% | -59.66% |
| EBITDA | 80.38% | 4.19% | -67.88% | -260.11% | -48.40% |
| EPS Basic | 85.60% | -30.09% | -132.83% | -526.48% | -3.75% |
| Normalized Basic EPS | 91.14% | 26.75% | -134.64% | -478.52% | -1.71% |
| EPS Diluted | 85.60% | -30.09% | -132.83% | -526.48% | -3.75% |
| Normalized Diluted EPS | 91.14% | 26.75% | -134.64% | -478.52% | -1.71% |
| Average Basic Shares Outstanding | 29.48% | 38.11% | 37.68% | 23.60% | 21.22% |
| Average Diluted Shares Outstanding | 29.48% | 38.11% | 37.68% | 23.60% | 21.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |